PDCD1 and non-small cell lung carcinoma: A recent phase 3 clinical trial enrolled 1274 patients with non-small-cell lung cancer (NSLC) and found that a PD-L1 TPS (tumour proportion score) of 50% or greater predicted a superior response to anti-PD-1 (Pembrolizumab) therapy compared to systemic chemotherapy, while a PD-L1 TPS of 1–49% predicted therapeutic equivalence70.